
    
      This crossover study aims at a comparison between 0.1 mmol/kg MultiHance and 0.1 mmol/kg
      Dotarem, between 0.05 MultiHance and 0.1 mmol/kg Dotarem in terms of diagnostic preference at
      CE-MRI in brain tumor patients to show superiority of MultiHance.
    
  